ArticleFrontiers in bioengineering and biotechnology2025
Injection of concentrated growth factors from plasma for treating large chronic lower-extremity ulcers defects.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of chronic lower-extremity ulcers is challenging, with a high ulcer recurrence rate.In chronic wounds, the healing process is stagnated in the inflammatory phase, characterized by persistent activation of the innate immune response. Compared with normal wounds, its environment is highly changed, with the downregulation of growth factor (GF) receptors because of resident low-mitogenic cells. Recently, the use of autologous growth factors has been shown to improve wound healing. We used concentrated growth factors extracted from plasma to treat chronic lower-extremity ulcers. The patients were treated with injections of concentrated growth factors extracted from autologous blood plasma. The wound condition was evaluated five days after each injection. The five patients received five injections of concentrated growth factors once a week. After two weeks, the area of the wound reduced, and the lipodermatosclerosis and abnormal pigmentation significantly improved. The wound was fully epithelialized after treatment. Injection of concentrated growth factors extracted from plasma may effectively treat chronic lower-extremity ulcers. However, the sample size may be relatively small, and we plan to continue collecting additional cases to minimize potential bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.